J. Allay

发表

Adenovirus p16 gene therapy for prostate cancer

J. Allay, M. Steiner, Yu Zhang, 2000, World Journal of Urology.

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors.

J. Allay, B. Sorrentino, Raymond L. Blakley, 1999, Progress in experimental tumor research.

Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells

A. Nienhuis, R. Wersto, J. Allay, 1998, Nature Medicine.

Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo.

Richard J Smeyne, A. Nienhuis, R. Ashmun, 1997, Blood.

High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells.

A. Nienhuis, R. Wersto, J. Allay, 2000, Blood.

In vivo selection of retrovirally transduced hematopoietic stem cells

R. Ashmun, J. Allay, B. Sorrentino, 1998, Nature Medicine.

Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors.

T. Lu, J. Allay, C. Dunbar, 2004, Blood.

Transrectal gene therapy of the prostate in the canine model

J. Allay, M. Steiner, C. Reed, 2002, Cancer Gene Therapy.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

KyungMann Kim, L. McGregor, J. Allay, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors.

J. Allay, S. Gerson, L. Shultz, 1997, Human gene therapy.

Role of DNA repair in resistance to drugs that alkylate O6 of guanine.

J. Allay, S. Gerson, O. Koç, 1996, Cancer treatment and research.

High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells.

J. Allay, D. Persons, E. Horwitz, 1999, Human gene therapy.

Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells.

J. Allay, S. Gerson, O. Koç, 1995, Blood.

Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.

P. Fagone, A. Nienhuis, J. Gray, 2011, Human gene therapy.

Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques transplanted with hematopoietic stem cells expressing dihydrofolate reductase vectors

T. Lu, J. Allay, C. Dunbar, 2003 .

Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.

J. Allay, B. Sorrentino, Raymond L. Blakley, 1997, Blood.

Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.

J. Allay, S. Gerson, O. Koç, 1996, Seminars in oncology.

Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

A. Nienhuis, J. Gray, M. Valentine, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainﬂuenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

J. Allay, C. Russell, P. Freiden, 2015 .

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

J. Allay, C. Russell, P. Freiden, 2014, Clinical and Vaccine Immunology.

Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors.

J. Allay, S. Gerson, O. Koç, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea.

J. Allay, S. Gerson, O. Koç, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells

J. Allay, B. Sorrentino, Raymond L. Blakley, 1998, Stem Cells.

Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells.

D. Patel, J. Allay, B. Sorrentino, 2000, Blood.

Retroviral transfer of the hENT 2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells

D. Patel, J. Allay, B. Sorrentino, 2000 .

Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice.

J. Allay, S. Gerson, B. M. Davis, 1997, Experimental hematology.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Michael Recht, Pratima Chowdary, Deepak Raj, 2014, The New England journal of medicine.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Pratima Chowdary, Savita Rangarajan, Cecilia Rosales, 2011, The New England journal of medicine.

Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B

M. Kay, A. Nienhuis, J. Gray, 2010 .

Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells.

Richard J Smeyne, A. Nienhuis, J. Cunningham, 2002, Blood.

Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis.

D Orlic, S. Jane, A. Nienhuis, 1999, Blood.

Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis.

A. Nienhuis, J. Gray, J. Allay, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

M. Kay, A. Nienhuis, J. Gray, 2014, The New England journal of medicine.